contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


combigene-presents-at-aktiedagen-goteborg-on-monday-16-may

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lärkberget is a Swedish investment company. The company's main areas of activity are direct investments in low-risk instruments, investments in listed shares, funds and other liquid asset classes, as well as participation in bridge loans and guarantee commitments, investments in unlisted profitable companies, and reverse acquisitions. Lärkberget is headquartered in Stockholm.

Lärkberget

On Monday May 16, 2022, CEO Jan Nilsson will present at Aktiedagen in Göteborg. In his presentation, Jan will talk about the company's two projects, the epilepsy project CG01, which is being...

<div class="mfn-body">On Monday May 16, 2022, CEO Jan Nilsson will present at Aktiedagen in Göteborg. In his presentation, Jan will talk about the company's two projects, the epilepsy project CG01, which is being developed together with Spark Therapeutics, and the lipodystrophy project CGT2. Jan will also talk about CombiGene's business development and ambitions to find additional gene therapy projects with high potential for value creation within CombiGene. &nbsp; CombiGene invites journalists, analysts, and shareholders to take part in the live broadcast at <a rel="nofollow noopener" href="http://www.aktiespararna.se/tv/live">www.aktiespararna.se/tv/live</a>. The event is open to everyone and does not require any membership in Aktiespararna. No registration is required to follow the event digitally. Use the opportunity to ask your questions to Jan Nilsson, by sending an SMS to 079-347 98 45 or email <a rel="nofollow noopener" href="mailto:event@aktiespararna.se">event@aktiespararna.se</a>. Your questions will be conveyed by Aktiespararna’s moderator during the Q&amp;A session that follows the presentation. You can also submit your questions now or during the presentation. &nbsp; Information When: Monday May 16, 2022, at 2.30 pm Live broadcast: <a rel="nofollow noopener" href="http://www.aktiespararna.se/tv/live">www.aktiespararna.se/tv/live</a></div><div class="mfn-footer mfn-contacts">Contacts<hr>Jan Nilsson, CEO Phone: +46 (0)704 66 31 63 <a rel="nofollow noopener" href="mailto:jan.nilsson@combigene.com">jan.nilsson@combigene.com</a>Bert&nbsp;Junno, Chairman of the board Phone:&nbsp;+46 (0)707 77 22 09 <a rel="nofollow noopener" href="mailto:bert.junno@combigene.com">bert.junno@combigene.com</a><a rel="nofollow noopener" href="http://www.combigene.com">www.combigene.com</a> CombiGene AB (publ)&nbsp;Agavägen&nbsp;52A, SE-181&nbsp;55&nbsp;Lidingö, Sweden <a rel="nofollow noopener" href="mailto:info@combigene.com">info@combigene.com</a></div><div class="mfn-footer mfn-about">About CombiGene<hr>CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. &nbsp; The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics. &nbsp; The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)8&nbsp;52 80 03 99, <a rel="nofollow noopener" href="mailto:info@fnca.se">info@fnca.se</a>.CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282. CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="nofollow noopener" href="https://storage.mfn.se/ec6390be-d2b8-46e5-bdd8-baed07fd0fdf/pm-aktiedagen-16-maj-2022-en.pdf" class="mfn-primary">PM Aktiedagen 16 Maj 2022 EN</a></div>